Raphael Pharmaceutical (RAPH) Equity Ratio (2020 - 2025)

Raphael Pharmaceutical has disclosed Equity Ratio across 6 years of filings, most recently posting 27.04 for Q4 2025.

• Equity Ratio for Q4 2025 came in at 27.04, up 1.61% year-over-year; the trailing twelve-month figure through Dec 2025 was 27.04 (up 1.61% YoY), and the FY2025 annual result was 27.04, up 1.61% from the prior year.
• Equity Ratio came in at 27.04 for Q4 2025 at Raphael Pharmaceutical, up from 180.57 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.6 in Q2 2022 to a low of 180.57 in Q3 2025.
• The 5-year median for Equity Ratio is 0.51 (2023), against an average of 16.31.
• Across the five-year window, Equity Ratio jumped 327.84% in 2021 and sank 6390.14% in 2024, its largest moves.
• Raphael Pharmaceutical's Equity Ratio stood at 0.3 in 2021, then gained by 4.95% to 0.32 in 2022, then jumped by 40.64% to 0.45 in 2023, then tumbled by 6238.39% to 27.48 in 2024, then increased by 1.61% to 27.04 in 2025.
• The last three Equity Ratio figures came in at 27.04 (Q4 2025), 180.57 (Q3 2025), and 34.93 (Q2 2025), per Business Quant data.